Both HD and NHL are chemosensitive diseases for which there is clear evidence of a dose-response curve (12). Consequently, the use of HGFs in the treatment of lymphoma is common practice. In general, both rHuG-CSF and rHuGM-CSF have been shown to improve a patient's tolerance to chemotherapy by decreasing the frequency of hospitalization, shortening the duration of neutropenia, and allowing for maintenance of dose intensity and timing (17,18,21,31). Furthermore, the treatment of older patients with conventional-dose chemotherapy is feasible with HGF supplementation

(13,14,16). Hematopoietic stem cell transplant is a well-recognized therapeutic option for patients with high-risk relapsed lymphoma. The success of this form of treatment has been greatly facilitated by the use of HGFs. The use of HGFs for vaccine therapies and as a potential adjunct to other biologic therapies seems promising but remains to be more fully investigated in clinical trials.

0 0

Post a comment